BioMarin Pharmaceutical Inc. (BMRN) Forecasted to Earn FY2022 Earnings of $4.80 Per Share
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Investment analysts at Wedbush issued their FY2022 EPS estimates for BioMarin Pharmaceutical in a report issued on Tuesday. Wedbush analyst L. Moussatos expects that the biotechnology company will earn $4.80 per share for the year. Wedbush has a “Outperform” rating and a $110.00 price objective on the stock.
BMRN has been the subject of a number of other research reports. JPMorgan Chase & Co. set a $130.00 target price on BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Sunday, October 29th. SunTrust Banks set a $115.00 target price on BioMarin Pharmaceutical and gave the company a “buy” rating in a report on Thursday, October 19th. Leerink Swann reaffirmed an “outperform” rating and set a $142.00 target price (up previously from $136.00) on shares of BioMarin Pharmaceutical in a report on Thursday, October 19th. BMO Capital Markets reaffirmed a “buy” rating and set a $117.00 target price on shares of BioMarin Pharmaceutical in a report on Friday, October 20th. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $124.00 target price (up previously from $114.00) on shares of BioMarin Pharmaceutical in a report on Thursday, October 19th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $111.60.
In other BioMarin Pharmaceutical news, EVP George Eric Davis sold 1,200 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $85.64, for a total value of $102,768.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Jean Jacques Bienaime sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, December 29th. The stock was sold at an average price of $89.75, for a total value of $1,795,000.00. The disclosure for this sale can be found here. Insiders have sold 90,750 shares of company stock valued at $8,159,588 in the last three months. 1.85% of the stock is owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. First Manhattan Co. boosted its stake in BioMarin Pharmaceutical by 104.2% in the fourth quarter. First Manhattan Co. now owns 1,225 shares of the biotechnology company’s stock worth $109,000 after buying an additional 625 shares in the last quarter. Toronto Dominion Bank boosted its stake in BioMarin Pharmaceutical by 12.9% in the second quarter. Toronto Dominion Bank now owns 2,124 shares of the biotechnology company’s stock worth $193,000 after buying an additional 243 shares in the last quarter. Commerce Bank purchased a new stake in BioMarin Pharmaceutical in the third quarter worth approximately $209,000. Teacher Retirement System of Texas purchased a new stake in BioMarin Pharmaceutical in the third quarter worth approximately $220,000. Finally, First Republic Investment Management Inc. purchased a new stake in BioMarin Pharmaceutical in the third quarter worth approximately $220,000. 98.83% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This article was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://theolympiareport.com/2018/02/11/biomarin-pharmaceutical-inc-bmrn-forecasted-to-earn-fy2022-earnings-of-4-80-per-share.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.